Last edition
News about "Dr Reddy Laboratories"
US FDA Approves Dr Reddy's Rituximab Biosimilar for the US Market
Dr Reddy's Laboratories has secured US FDA approval for its rituximab biosimilar, expanding its global biosimilars portfolio and strengthening its presence in the US biologics market.
Dr Reddy Laboratories | 03/08/2026 | By News Bureau
Dr. Reddy's Delays Semaglutide Supplies Following API-Related Quality Issue
Dr. Reddy's Laboratories announces a temporary delay in commercial supplies of semaglutide after identifying an API-related quality issue affecting certain batches. The company is investigating the root cause and has confirmed that patient safety and existing global regulatory filings remain unaffected.
Dr Reddy Laboratories | 09/07/2026 | By News Bureau
Dr. Reddys API plant in Hyderabad gets EIR from U.S. FDA
Dr. Reddy’s API plant in Hyderabad gets EIR from U.S. FDA
Dr Reddy Laboratories | 08/08/2023 | By Sudeep Soparkar | 1831
Dr. Reddy's Laboratories Limited's API facility at Srikakulam completes USFDA inspection successfully
Dr Reddy Laboratories | 20/07/2023 | By Sudeep Soparkar | 2796
JB Pharma acquires four paediatric brands from Dr Reddy's Laboratories
The total covered market size of four brands – Z&D, Pedicloryl, Pecef and Ezinapi combined is Rs 1800 crores
Dr Reddy Laboratories | 01/07/2022 | By Sudeep Soparkar | 702
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy